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The emerging evidence that DNA vaccines elicit a protective
immune response in rodents, dogs and cancer patients,
coupled with the US Food and Drug Administration (FDA)
approval of an initial DNA vaccine to treat canine tumors is
beginning to close the gap between the optimistic
experimental data and their difficult application in a clinical
setting. Here we review a series of conceptual and biotechno-
logical advances that are working together to make DNA
vaccines targeting molecules that play important roles during
cancer progression (oncoantigens) a promise with near-term
clinical impact.
Once we made a promise we swore we’d always remember
No retreat, baby, no surrender
Blood brothers in a stormy night
With a vow to defend
No retreat, baby, no surrender
No Surrender, Bruce Springsteen
Introduction
The promise of antitumor vaccines rests on their ability to trigger
a long-lasting protection against a tumor with virtually no side
effects. This promise is underpinned by data from countless
vaccination-tumor challenge experiments.1-3 It must be admitted
that these vaccines have generated both waves of enthusiasm
and total disillusionment. Even so, the fascinating possibility
of controlling tumor spread through a vaccine-elicited adaptive
immune response is such as to continue to spur the search for
better tumor antigens and more efficient vaccination modalities.4
DNA vaccines are a precision tool for activating effective
immunity against cancer.5 Their potential impact is illustrated
by the first one approved by FDA in the January 2010 for the
treatment of advanced canine melanoma, namely OnceptTM
(Merial, Duluth, GA), a plasmid coding for human tyrosinase.6
The emerging information should also speed up the translation
of new immunotherapies to patients since initiation and
progression of canine and human cancers are influenced by
similar factors.
However, DNA vaccines are still a promise that may appear far
from being an established cancer therapy. Here we are teasing
apart a few of the technological and conceptual advances working
together to make DNA vaccines targeting oncoantigens, i.e.,
molecules that play important roles during cancer progression and
that can be attached by immune reactivity, a promise with near-
term clinical impact.
DNA Vaccines: What are They?
In DNA vaccines the antigen is replaced by its blueprint. When
administered, DNA causes the expression of the protein that
induce the immune response. Recombinant DNA technologies
have facilitated the preparation of plasmids as compared with
conventional vaccines. Adjuvant sequences can be embedded in
the plasmid. These reasons make DNA vaccination popular in
preclinical experiments involving rodents where it elicits cell and
antibody-mediated responses to a variety of antigens. The amount
of protein expressed, its persistence and the kind of antigen
presentation are key variables that determine the efficacy of the
protection thus elicited. See references 5 and 7 for excellent
reviews on DNA vaccination in cancer.
Basically, a DNA vaccine consists in a circular double strand
bacterial DNA (the plasmid) in which a few eukaryotic and
synthetic sequences has been inserted. To minimize the possibility
of plasmid integration into host chromosomes, these are limited
to the antigen sequence, an ubiquitary enhancer-promoter driving
its expression and a transcription termination site. To permit
insertion of the sequence coding for the antigen, the plasmid
should also contain a synthetic 100 base pairs DNA sequence
(the multiple cloning site). The presence of a “relaxed origin of
replication” and an antibiotic-resistance gene allows efficient
plasmid replication in bacterial cells and their selection, two key
aspects for high-scale plasmid production. When employment of
a plasmid in clinical trials is envisaged, the antibiotic-resistance
should not involve antibiotics commonly used in human
infections and should be less likely to elicit allergic reactions.
The pVAX1 plasmid (Invitrogen) containing the Kanamycin
resistance gene meets the FDA’s requirements for vectors to be
used in patients.
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In Vivo Electroporation: The DNA Vaccinologist’s
Dirty Little Secret
There are several ways of delivering a naked plasmid. Its
intramuscular injection is enough to elicit an immune response
in experimental rodents and humans.8,9 The response is enhanced
by the manipulation of the muscle through substances toxic for
muscle cells10 or its surgical exposure.11 The plasmid can be
enclosed in cationic liposomes to protect it against nucleases12
or shot into the dermis after coating it on gold particles by
exploiting a “gene gun”13 or jet-injectors.14 Lastly, a rapid immune
response follows tattooing of a plasmid into the skin.15
Just as adjuvants are the “immunologist’s dirty little secret”16 to
increase the efficacy of a vaccine, electroporation is the dirty little
secret that enhances the efficacy of DNA vaccines:
(A) by facilitating plasmid entry into target cells;
(B) by acting as an adjuvant that induces local tissue damage
eventually attracting an inflammatory infiltrate.
Delivery of short electrical pulses to the injection site causes
temporary permeabilization of the cell membrane. Entry of the
plasmid into the cell is facilitated and inter-individual variability
of the response is minimized.17,18 Sophisticated electroporators
have rendered plasmid electroporation a common way of securing
efficient DNA immunization in animals19 and patients.20
Electroporators deliver pulses at a voltage that may be fixed or
regulated to take account of tissue resistance. The number and
kind of electric pulses, their voltage and their delivery through
plaques applied on the skin or by needles determine the kind and
intensity of the response elicited. In part this is due to the efficacy
of the penetration of the plasmid into the cell. On the other hand,
the kind of injury provoked by both needle insertion and electric
pulses play a role in deciding the form and extent of cell death and
the release of necrotic debris or apoptotic bodies. The type and
amount of cell death influences the recruitment of distinct
reactive cells releasing idiosyncratic repertoires of cytokines. These
inflammatory cells are differently able to both take up and present
the antigen secreted by transfected cells and cross present antigen-
expressing cell debris released by the dying cells.
The Igea Cliniporator is a fixed voltage, clinical device adopted
to improve the penetration of bleomicin into cancer lesions.21 It
can also be set to improve DNA vaccination. A morphological
analysis of the events following intramuscular injection and
electroporation of a plasmid22 shows that damaged myofibers
first become infiltrated by granulocytes, then by macrophages,
dendritic cells (DC) and later by B and T cells (Fig. 1). The
numerous contacts between macrophages, DC, T cells and
antigen expressing myofibers suggests that both a direct antigen
presentation and macrophage and DC-mediated antigen cross-
presentation may occur in the electroporated muscle. By contrast,
the reaction of the draining lymph nodes is weak.
Exogenous Adjuvants
As the environment plays a major role in modulating the res-
ponse that ensues after delivery of a plasmid, we have set out
to determine whether adjuvants enhance the immune response
elicited in mice by the intramuscular injection or electropora-
tion of a plasmid (RRTErbB-2) coding for the extracellular and
transmembrane domains of rat ErbB-2 oncogene.11,23,24
LAG-3 (lymphocyte activation gene-3/CD223) is a type I
transmembrane protein associated with the T cell receptor
(TCR)–CD3 complex. Administration of soluble LAG-3, gener-
ated by fusing the extracellular domain of murine LAG-3 to
murine IgG2a Fc portion, in the area in which RRTErbB-2 has been
injected potentiates the vaccination by eliciting a stronger CD8+
T cell activity, a sustained secretion of both interferon-gamma
(IFNc) and IL-4, and the expansion of CD8+/CD11b+/CD28+
effector and CD8+/CD11b+/CD28- effector-memory T cells.
Combination of plasmid injection with soluble LAG-3 also leads
to higher titers of anti-rat ErbB-2 antibodies with a faster shift
toward IgG2a. In mammary cancer prone rat ErbB-2-transgenic
BALB/c mice (BALB-neuT mice) this enhanced response goes
along with a sustained protection against the onset of mammary
lesions.25
Remarkably, even the higher immune response that follows
RRTErbB-2 electroporation in BALB-neuT mice is further
enhanced by intravenous administration of BAT monoclonal
antibodies (mAb) (CureTech). The stronger anti-rat ErbB-2
T cell and antibody-mediated immune response thus elicited
results in even better protection.26 These BAT mAb bind the
programmed death-1 (PD-1) receptor of the B7 family expressed
on T cells after activation.27 Following the interaction with its
ligands (PDL-1 and PDL-2) PD-1 downregulates TCR signals
and promotes T cell anergy and apoptosis. By blocking this
suppressive loop, BAT mAb enhance T-cell response and leads
to potent anti-tumor immunity both in mouse models and in
patients with advanced hematologic cancer.27
Lactoferrin, a glycoprotein of the transferrin superfamily,
plays several distinct activities in immunity. We have shown
that repeated oral administrations of a recombinant human
lactoferrin (Talactoferrin, TLF, Agennix) hamper the onset of
mammary carcinomas in BALB-neuT mice.28 Association of
oral TLF with RRTErbB-2 electroporation extends tumor-free
interval, decreases the number of palpable tumors/mouse, and
augments vaccine-induced response as compared with sole
RRTErbB-2 electroporation.
Build-In Adjuvants
Hypomethylated CpG dinucleotide-containing motifs present
or inserted in the bacterial plasmid trigger innate immune
activities and help to shape the adaptive response elicited by
the vaccine. Similarly, pattern recognition receptors that sense
intracellular DNA can be used to harness the intrinsic immune-
stimulating properties of DNA vaccines. A plasmid encoding
the cytosolic DNA-dependent activator of interferon regulatory
factors co-injected with antigen-encoding plasmids enhances
antigen-specific proliferation and induction of effector and
memory T cells.29
In principle, cytokines are excellent adjuvants for DNA
vaccines, either as recombinant proteins or as embodied genes.
They may increase the response and thus allow selective activation
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of particular reaction mechanisms. We have shown that the
nonapeptide VQGEESNDK corresponding to the 163–171
amino acids of the human IL1β retains several of the
immunostimulatory properties while it is free from the potent
proinflammatory properties of the entire molecule and increases
the immunogenicity of poorly immunogenic tumors.30 When
BALB-neuT mice were immunized with RRTErbB-2 plasmids in
which the sequence of this nonapeptide was inserted, a higher
anti-rat ErbB2 antibody response accompanied by a massive
lymphocyte infiltration of the mammary lesions went along with
a stronger protection against mammary tumors.31
One of the most effective non-DNA vaccines against ErbB-2,
the “Triplex ” vaccine, is based on mammary carcinoma cells
expressing both the rat ErbB-2 protein and allogeneic class I major
histocompatibility complex (MHC) glycoproteins administered
in combination with recombinant IL-12.32 By replacing the
recombinant cytokine with cytokine gene-engineered cells, it was
possible to compare the efficacy of IFNc, IL-2, IL-12, and IL-15.
In cancer prone ErbB-2 transgenic mice IL-12 was vastly superior
to other cytokines.33 The translation of the Triplex design from
cell-based to a DNA vaccine, using a mixture of three plasmids:
RRTErbb2, a plasmid encoding full length H-2Dq MHC gene and
another plasmid encoding mouse IL-12, showed that cell-based
and the DNA Triplex vaccines were equally effective.34 However,
in most instances vaccination with the RRTErbb2 plasmid alone
elicited a protection similar to that obtained with the Triplex
plasmids. This finding was surprising since our previous
experience with cell-based vaccines had shown that the Triplex
design yielded vastly superior protection from tumor onset in
comparison to any subset of its components.32 Our results show
that the strong immunity elicited by the RRTErbB-2 plasmid,
already helped by embedded CpG sequences and by electropora-
tion, is less dependent than analogous cell vaccines on the
adjuvant activity of cytokines.
Lastly, construction of more sophisticated plasmids results in
the induction of better immune responses by simultaneously
relieving from suppression. Plasmids can thus be endowed with
two expression cassettes, one coding for the antigen, the other
Figure 1. Cellular events following intramuscular electroporation of 50 mg of plasmid in 20 ml of saline through Cliniporator (Igea, Carpi, Italy). Insertion of
the electroporator needles into the quadriceps muscle of the mouse and delivery of two low voltage pulses of 150V of 25 ms with a 300 ms interval (A).
One-6 h later the damaged myofibers and cell debris (dotted yellow) are surrounded by polymorphonuclear (N) and mononuclear leukocytes (MW) (B).
One or two days later mature and differentiated tissue macrophages (MW) and dendritic cells (DC) progressively become prominent among
inflammatory cells infiltrating the numerous necrotic myofibers (C). On the third-fourth day from the electroporation, intact and regenerating muscular
fibers (pale red) are overexpressing the protein encoded by the plasmid (green triangles), while the area is being infiltrated by B (B), T (T) and dendritic
cells (DC). Interestingly, CD11b+ macrophages and CD11c+ DC and, later, CD4+ T cells are often in direct contact with antigen expressing muscle cells or
antigen expressing fragments and each other (D).
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expressing a shRNA able to silence those molecules that negatively
control the immune response.35 This shRNA-mediated interfer-
ence with regulatory mechanisms only concerns plasmid-
transfected antigen-presenting cells. When the ability of these
transfected cells to induce an efficient immune response is
disturbed by a tumor, neutralization of tumor-borne regulatory
factors may result in an efficient presentation of oncoantigen
peptides.36
The Sequence Coding for the Antigen
Fine modifications of the sequence coding for the antigen protein
lead to major differences in protein processing and immunogeni-
city.5 Addition of a signal peptide or an ubiquitine signal to the
N-terminus of the antigen sends the encoded protein toward the
extracellular microenvironment through the endoplasmic reticu-
lum or toward the proteasome for processing and presentation by
MHC class I glycoproteins,37 whereas it goes to the plasma
membrane when idrophobic sequences are added to the C-
terminus. Addition of a lysosomal targeting signal drives its
presentation by MHC class II glycoproteins.38
The adaptive response elicited by the antigen can be “helped”
by inserting additional sequences and obtaining an encoded
protein fusing the antigen with these sequences.5 The fusion
proteins containing tumor antigens and epitopes of the tetanus
toxin engage T helper cells induced by a previous anti-tetanus
immunization in the response against the tumor antigen.
By exploiting receptors of different kind, the fusion antigen can
be selectively targeted toward antigen presenting cells to empower
them to in vivo priming of CD8+ T cells. When mice were
electroporated with a plasmid encoding amino acid 364–391 of
human ErbB-2 fused with the Fc domain of a human IgG1 (Fc-
ErbB-2364–391), the better CD8 T cell-mediated response toward
human ErbB-2 epitopes was paralleled by a stronger protection
against a challenge of human ErbB-2+ mammary cancer cells.39
Another way we explored to get a more selective delivery of
tumor antigens is to generate a plasmid coding for the antigen
fused with the extracellular domain of CTLA-4, a receptor
binding to the co-stimulatory B7 (CD86) molecules on DC.
Following the injection in mice of a plasmid coding for the NH-
terminal 222-amino acids of human ErbB-2 fused with the
extracellular domain of human CTLA-4 we observed an enhanced
anti-human ErbB-2 humoral and T cell mediated response and
protection against a challenge with mouse tumor cells expressing
human ErbB-2. A similar plasmid encoding a fusion CTLA-4-
ErbB-2 mouse protein markedly delayed the onset of mammary
carcinomas in BALB-neuT mice.40
We also searched for the smallest rat ErbB-2 epitope still able to
elicit a protective response. Our starting point was the observation
that RRTErbB-2 plasmid elicits a similar or even better response
than the one encoding the full length rat ErbB-2.11 Then, we
produced seven plasmids encoding the transmembrane domain
associated with decreasing fragments of the extracellular domain.41
When these plasmids were electroporated in wild-type BALB/c
mice, the intensity of the response and protection against a
challenge of rat ErbB-2+ murine cells decreased with the
shortening of the ErbB-2 fragment encoded. Surprisingly,
immunization with the RRTErbB-2311–689 plasmid encoding a
fragment lacking the first 311 amino acids of the ErbB-2
extracellular domain still afforded full protection. In BALB-neuT
mice electroporation of RRTErbB-2311–689 induces a protection
comparable to that elicited by RRTErbB-2. Its location in the
transfected cell and the conformation acquired by the short
fragment encoded probably allows a favorable exposition of
critical ErbB-2 epitopes.41
One of the problems linked to the use of oncoantigens as a
target is that they are self-tolerated molecules. Therefore, a vaccine
should be able to induce an autoimmune response overcoming
central and peripheral tolerance to self.42,43 Both the induction
and the persistence of an immune response are markedly hindered
by natural Treg cells that expand in response to the overexpression
of self oncoantigens by the tumor. The “regulatory memory”
constantly tuning down the immune response to self antigens44
makes the induction of an effective response to oncoantigens
difficult, and make it necessary to continuously boost the
vaccination to maintain its efficacy.45
Vaccination with xenogeneic ortholog antigens is an effective
way to break self tolerance. Heterologous antigens activate both
bystander anergic B and T cells and prime T cells. However, the
cross-reactive response to self antigens may be of low intensity and
affinity.46 When wild-type mice and mice transgenic and tolerant
for the rat or the human ErbB-2 are immunized with plasmids
encoding the extracellular and transmembrane domains of the
fully human (HuHuTErbB-2) or fully rat ErbB-2 (RRTErbB-2), the
response shows a consummate specificity to the rat or human
ErbB-2 ortholog used as antigen but a poor cross-reactivity toward
the ortholog expressed by the mouse and its tumors (Fig. 2). This
“orthologue restriction” corresponds to a similar restriction in the
ability to inhibit the growth of tumors expressing the human or
rat ErbB-2 ortholog.22 To overcome it we immunized mice with
plasmids coding for ErbB-2 proteins composed in part by rat and
by human sequences. The homologous moiety guarantees the
specificity of the response while the hetereologous moiety ensures
better overcoming of tolerance (Fig. 2). Vaccination of wild-type
mice and mice transgenic for the rat or the human ErbB-2 with
these chimeric plasmids elicits a stronger and more cross-reactive
response and a better protection than fully human or fully rat
plasmids against carcinomas overexpressing either rat or human
ErbB-2.22,45,47
Oncoantigens, Why?
Tumor’s genetic instability often thwarts the immune attack
because it results in the selection of clones that do no longer
express the target antigen or express it in a way that it cannot be
perceived by T cells.48,49 A conceptual quantum jump in planning
new generation vaccines is to target the vaccine against
oncoantigens since these are molecules not (easily) disposable
during tumor progression nor are they easy to hide because of
their indispensable role. Oncoantigen-loss variants can occur, but
they will get a crippled tumorigenic potential and negative
selection.50 Otherwise, the function of the targeted oncoantigen
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can be taken by its replacement by one that will offer a further
target.51
Besides its selection of antigen-loss variants, a tumor escapes
T cell recognition through impairment of antigen processing
machinery and downmodulation of MHC glycoproteins.
However, because of their function, oncoantigens are often
accessible to vaccine-induced antibodies.52 Their diverse functions
and localizations (Fig. 3) thus allows their targeting by different
immune mechanisms, among which those mediated by anti-
body may acquire a prominent role. Antibodies may directly
block their function, activate complement-mediated lythic and
inflammatory mechanisms, mediate antibody and comple-
ment dependent cytotoxicity, and give rise to immune
complexes triggering additional immune responses and epitope
spreading.55,58
The evidence of an important role of vaccine-elicited antibodies
in controlling the onset and expansion of a tumor constitutes a
second conceptual quantum leap afforded by vaccines against
oncoantigens. Despite the persistent T cell chauvinisms, DNA
vaccines against oncoantigens should be planned to elicit both
humoral and cellular immunity and not solely a T cell-mediated
immunity.32,51,59
Figure 2. Immunogenicity of chimeric proteins coded by rat-human (RHuTErbB-2) and human-rat (HuRTErbB-2) plasmids. RHuTErbB-2 encodes for a protein in
which the 410 NH2-terminal residues are from the rat ErbB-2 extracellular domain and the remaining residues from human ErbB-2. HuRTErbB-2 encodes for
a protein in which the 390 NH2-terminal residues are from human ErbB-2 and the remainder from rat ErbB-2 (A). The ability of B cells (B) to present not-
tolerated peptides contributes to production of an antibody response to both the tolerated and not-tolerated moieties of the antigen. Following a DNA
electroporation of a rat ErbB-2 tolerant mouse muscle with a plasmid encoding for a rat (orange) and human (blue) chimeric ErbB-2 protein (RHuTErbB-2 or
HuRTErbB-2), T cells (T) recognizing the xenogeneic human peptides expands. The expanded T cells interact and provide helper signals to B cells by
recognizing not-tolerated human peptides (blue triangles) presented by MHC II molecules on the cell membrane of B cells. The interaction between T
and B cells recognizing human moiety of the encoded vaccine leads to the production by plasmacells (PC) of antibodies (blue Y) to the xenogeneic
human moiety. By contrast, the interaction of expanded T cells with B cells specific for a tolerated rat moiety help to break immune tolerance to self
protein leading to the production by plasmacells (PC) of antibodies (orange Y) to the tolerated rat moiety (B). ErbB-2 ortholog recognized by antibodies
produced by mice following electroporation with plasmids encoding fully rat (RRTErbB-2), fully human (HuHuTErbB-2), and rat-human chimeric (RHuTErbB-2,
HuRTErbB-2) extracellular and trasmembrane domain of ErbB-2 (C).
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On the Search for Fresh Oncoantigens
The “rite of passage” that marks a tumor antigen to become a
verified oncoantigen has two phases:
(A) The disclosure of a functional role of the molecule in
fostering the transformed phenotype of a given (human)
neoplasm, i.e. the “onco” portion of the oncoantigen definition;
(B) The evidence that the immune system recognizes the
molecule and mounts an effective response affecting tumor
progression, i.e. the “antigen” part.
The identification of oncoantigens moves from the consideration
that the progression of carcinogenesis requires the activation of
specific genes and may be altered when these are inhibited. The
characterization of genes differentially activated during cancer
progression should lead to the identification of prominent targets
against which to trigger the immune response. Microarray trans-
cription analysis highlights several gene signatures that differentiate
successive stages of tumor progression in transgenic mice. Of the
transcripts upregulated going from pre-neoplasia to overt cancer,
only those that have an ortholog in humans, low expression in
normal human tissues, and a high and homogeneous expression in
human cancers are selected as “putative” oncoantigens.53 The most
promising are those that may be targeted by both antibodies and
T cells. They are then validated by immunizing cancer-prone
transgenic mice with DNA vaccines targeting them.53,55 For a
provisional inventory of putative and verified oncoantigens see
reference 52.
In many cases vaccines targeting oncoantigens afford cancer-
prone genetically engineered mice a life-long protection. By
contrast, in the management of minimal residual disease or in
the presence of recurrences and metastases, their potential is
limited.52,58,60 Greater efficacy could be achieved by targeting
oncoantigens expressed by cancer initiating cells (CIC) respons-
ible for the progression, metastasis, resistance to therapy, and
recurrence of many kinds of tumors. To identify oncoantigens
expressed by CIC of mammary cancer we are performing a
comparative transcriptomic analysis of the bulk of tumor cells
from transgenic mice with that of CIC-enriched serial sphere
passages of the same tumor cells.61 Subsequent integration of these
mouse data with those from human breast cancer will allow the
selection of oncoantigens involved in the maintenance of the
CIC-like features of mouse and human cancer. Fresh DNA
Figure 3. Precise oncoantigen classification (A). Validated class I, II and III oncoantigens present in various tumor compartments currently targeted by our
therapeutic vaccines (B). Comp,53 (black ♌) and Angiomotin 1,54 (red Y) are validated class I oncoantigens expressed on tumor extracellular matrix and on
tumor vasculature respectively (left panel). ErbB-2,55 (blue Y), Epsin, (brown E), Claudin,53 (green C) and CSPG4,56 (purple f ) are class II oncoantigens
expressed on tumor cell membrane (middle panel). The protein product of the NPM-ALK translocation,57 (ALK, purple♒) and BIRC5,53 (orange b) are class
III oncoantigens present in the cytoplasm and nucleus of carcinomas and lymphomas (right panel). Several additional molecule endowed with the
properties of oncoantigens have been validated in immunization assay by other laboratories.58
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vaccines targeting these newly identified CIC oncoantigens may
extend vaccine efficacy.36
Models for Oncoantigen Validation
During the long-lasting relationship between a tumor and its
environment, antibodies against oncoantigens play diverse roles.
These roles are prominent precisely because an oncoantigen is
both a tumor target and a molecule with a functional role in
tumor progression.55 The importance of vaccine-elicited antibod-
ies against oncoantigens is one of the lessons emerging from the
studies on genetically engineered mice developing autochthonous
cancers. Immunization experiments carried on these mice, on the
other hand, illustrate the limit of an anti-oncoantigen vaccine. It
can keep an incipient tumor at bay for a very long time.23
However, the efficacy of vaccine-induced protection fades when
the vaccine is first administered to mice already bearing clinically
evident tumors.23,57 In a therapeutic setting the protection
afforded by an effective oncoantigen vaccine is often similar to
that observed in “successful” clinical trials with anti-tumor
vaccines: a statistically significant delay in tumor progression,
but of little weight in the life of a patient.
Since experimental models are so critical in assessment of the
weight of the immune mechanisms involved in tumor protection,
those that ever more closely reproduce the human situation
should be sought. Genetically engineered mice with profound and
stable immunodeficiencies have been transplanted with a human
immune system and used to investigate and manipulate, in a
murine context, human immunity against human tumors.62 Even
in their present, imperfect state of development, these mice can be
used not only to study the development of human immune
components, but also to better define a few critical features of
vaccines against oncoantigens (Fig. 4).
Lastly, it should be borne in mind that many aspects of the
immune response can be captured by mathematical models ranging
from system-level models that describe the immune system as a
whole to extremely fine-grained ones that analyze a single cellular or
molecular response.64 The latest generation of models is beginning to
tackle practical problems. Both the general field of vaccines and
tumor immunology especially can derive great practical benefits.65
Climbing Over the Limit
Experiments with genetically engineered mice have furnished
bitter evidence of the limit of DNA vaccines against oncoantigens.
When an oncoantigen vaccine is administered to a healthy mouse
genetically predestined to die because of a specific cancer, repeated
boosts keep it tumor free for a period of time that may equate its
natural life span. However, when the same vaccine is administered
to a mouse with more advanced stages of microscopic lesions, the
protection gradually fades away.66 As mentioned above, vaccine
combination with adjuvants of different kind variously extends
the efficacy of vaccine-elicited protection.25,26 A further extension
is obtained by manipulating the sequence coding for the antigen
protein.45 However, as the time of the first vaccine administration
approaches the stages of a clinical tumor diagnosis, vaccine
efficacy disappears. A pattern of this kind is shared by different
combinations of vaccine in genetically engineered mice confining
the exploitation of oncoantigen vaccines to the awkward field of
tumor prevention.58 It also spurs the search for a way to make
oncoantigen vaccine of significance in tumor therapy. Probably
multiple factors contribute to the shortfall of vaccine efficacy. The
progression of tumor renders the microscopic lesions and
incipient tumors less permeable to immune attack. Moreover, a
series of factors released by the tumor together with the increasing
overexpression of the targeted oncoantigen results in an expansion
Figure 4. Human immune system-engrafted (HIS) mice for validation of oncoantigen vaccines. Human hematopoietic stem cells implanted in severely
immunodeficient mice give rise to a (more or less) functional human immune system (A) that can be subsequently vaccinated with human tumor
antigens to investigate and manipulate in an experimental context human anti-tumor immunity, (B and C). Note that most current protocols use human
progenitors from cord blood for the engraftment, hence the final step shown in the figure, i.e. challenge with human (adult) tumor cells, could entail
MHC allogeneic interactions. Human immune system-engrafted mice are undergoing continuous improvements, because the interactions of xenogeneic
human and murine molecules is not always functional. Novel models include additional genes encoding for human MHC, to humanize antigen
presentation, or human species-specific cytokines to enhance human cell long-term survival and functional differentiation.63
322 OncoImmunology Volume 1 Issue 3
of regulatory cells that suppress the induction, effector and
memory phases of anti-tumor immune response. The importance
of these tumor-driven negative regulations is evident in mice
bearing slow growing autochthonous cancer as well as in patients
with a clinically evident tumor.
Almost paradigmatically BALB-neuT mice show that during
the slow progression of their mammary lesions immature myeloid
cells,67 suppressive NKT cells68 and natural Treg cells42 expand. As
the availability of anti-CD25 mAb allows a simple even if gross
interference with Treg cells, we assessed how a temporary
interference with Treg cells extend vaccine efficacy. In BALB-
neuT mice central tolerance activated by ErbB-2 expression in the
thymus and its overexpression in the mammary lesions lead to the
deletion of CD8+ T cell clones reacting at high affinity with
dominant ErbB-2 epitopes. Because of this deletion, anti-ErbB-2
DNA vaccination elicits solely CD4+ cell expansion and anti-
ErbB-2 antibodies.23,69,70 However, the combination of DNA
vaccination with the depletion of Treg cells triggers a higher
antibody response combined with the onset of a CD8+ cytotoxic
response against the ErbB-2 immunodominant epitope. This
unexpected cytotoxic response is due to the freeing of a latent pool
of low-avidity CD8+ T cells bearing cryptic TCR from Treg
constraints. The stronger and composite response elicited inhibits
cancer progression at stages in which the vaccine alone is
ineffective. While dramatic, this extension of vaccine efficacy is no
longer able to secure mice survival when diffuse and invasive
microscopic cancers become palpable.43
These results suggest that a more sophisticated interference
with tumor-borne regulatory and suppressor mechanisms may
serve to endow oncoantigen vaccines with therapeutic efficacy.
The exploitation of the plasmids both coding for the antigen and
expressing shRNA able to silence molecules that negatively
control the immune response may offer new ways to extend
oncoantigen vaccine efficacy.36
Conclusions: First Fulfillments of the Promise
The antibody and cell mediated response elicited by the
electroporation of HuRTErbB-2 plasmid in healthy dogs and in
pet dogs after the surgical removal of mammary cancer proves the
efficacy of DNA vaccines electroporation in higher animals
(Cavallo F, unpublished results). Moving from this evidence, we
started a clinical trial in pet dogs with advanced mucosal
malignant melanoma to assess the potential of the electroporation
of a plasmid coding for the human chondroitin sulfate
proteoglycan-4 (CSPG4), a molecule highly expressed by human
and dog melanomas whereas it has a restricted distribution in
normal tissues.71 Dogs with biopsy-confirmed CSPG4+ malignant
melanoma and absence of metastases beyond the first regional
lymph nodes were subjected to surgery and then electroporated at
monthly intervals with a plasmid coding for human CSPG4. In all
dogs the vaccine elicited antibodies to human CSPG4. Their
cross-reactivity with the canine ortholog shows that the plasmid
coding for this heterologous molecule effectively breaks immune
tolerance to dog CSPG4. So far, the intensity of the elicited
immune response appears to go along with the extension of the
time of tumor recurrence and dog survival (Cavallo F et al., in
preparation).
Preliminary data from ongoing trials with cancer patients are
showing that DNA vaccines induce immune responses that goes
along with an inhibition of tumor progression.52,72 When
plasmids are electroporated, the response elicited in patients with
recurrent prostate cancer is much higher than that triggered by the
sole injection of the plasmid.20 Italian authorities have recently
approved a phase I/II clinical trial based on repeated electropora-
tions of the chimeric RHuTErbB-2 plasmid in patients in whom a
primary advanced ErbB-2+ squamous carcinomas of the oral
cavity, oropharynx, hypopharynx has been surgically removed
(EudraCT, 2011-001104-34). Both the implemented dog trial
with CSPG4 and the incipient trial with RHuTErbB-2 plasmids are
aimed to exploit the immune response not to cure an existing
cancer, but to extend the tumor free survival and delay tumor
relapse.
Admittedly, all the forthcoming and ongoing clinical trials are
still far from fulfilling the therapeutic promise of DNA vaccine
against oncoantigens, but hopefully they are putting a solid case
for it. No retreat and no surrenders!
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